Is it necessary to insist on taking EIKANCE 0.01% Atropine Sulfate Eye Drops for a long time without stopping?

0.01% atropine sulfate eye drops (trade name EIKANCE) is a low-concentration atropine eye drop, mainly used to control myopia in children and slow down the progression of myopia. Many parents and patients are concerned about whether the drug must be used long-term and whether it can be discontinued. This article will provide a detailed explanation of the drug's mechanism of action, clinical medication recommendations, drug withdrawal risks, and individualized treatment.

Atropine sulfate in EIKANCE blocks the M-type choline receptors in the eye and slows down the growth of the axial length of the eyeball, thereby effectively delaying the progression of myopia. Since the progression of myopia is often a long-term and slow process, it is difficult to achieve lasting effects with a single or short-term medication. Therefore, clinically it is usually recommended that patients adhere to long-term use according to the guidance of their doctor, especially in the stage of rapid myopia progression. Long-term medication can maximize the control effect of the medication, help children stabilize their vision, and reduce the risk of high myopia and its complications.

Although long-term medication is beneficial for controlling myopia, this does not mean that EIKANCE cannot be discontinued. After some patients reach the treatment goals or the progression of myopia is significantly slowed down, doctors may consider gradually reducing the dosage or even discontinuing the medication depending on the specific circumstances. You need to be careful when stopping the medication, because sudden discontinuation may cause myopia to rebound and rapidly deepen. Therefore, the drug withdrawal program is usually gradual, and through close monitoring and follow-up by doctors, the treatment program can be adjusted in a timely manner to reduce adverse effects.
Individual differences lead to differences in medication times and regimens. Different children have different myopia progression rates, eye physiological structures, and responses to medications, so medication plans should be individually formulated. Doctors will dynamically evaluate the effects and risks of medication based on multiple factors such as visual acuity examination, changes in axial length of the eye, and patient age, and decide whether to continue using EIKANCE or adjust the dosage. This personalized management strategy helps to reduce possible side effects caused by long-term medication while ensuring efficacy.
In short, 0.01% atropine sulfate eye drops (EIKANCE) usually requires long-term use to effectively control the progression of myopia, but discontinuation is not absolutely impossible. Patients should strictly follow the instructions of their ophthalmologists and conduct rational medication and monitoring according to the specific situation. Scientific and standardized medication and regular review are the keys to ensuring successful treatment and protecting vision health.
Reference: https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf